Rapport Therapeutics, Inc. Common Stock (RAPP) Fundamentals 2026 — Revenue Analysis | SniperIQ
Rapport Therapeutics, Inc. Common Stock (RAPP) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Rapport Therapeutics, Inc. Common Stock's market cap?
Rapport Therapeutics, Inc. Common Stock (RAPP) has a market capitalization of approximately
What is Rapport Therapeutics, Inc. Common Stock's P/E ratio?
Rapport Therapeutics, Inc. Common Stock's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Rapport Therapeutics, Inc. Common Stock?
Rapport Therapeutics, Inc. Common Stock runs a net profit margin of -536.4%, a gross margin of 96.3%, and an operating margin of -611.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Rapport Therapeutics, Inc. Common Stock pay a dividend?
Rapport Therapeutics, Inc. Common Stock does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Rapport Therapeutics, Inc. Common Stock financially healthy?
Rapport Therapeutics, Inc. Common Stock carries a debt-to-equity ratio of 0.02x and a current ratio of 27.08x, with a market beta of 0.95. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Rapport Therapeutics, Inc. Common Stock a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Rapport Therapeutics, Inc. Common Stock (RAPP) the key facts are: market cap
Track Rapport Therapeutics, Inc. Common Stock's full fundamentals live
Get Rapport Therapeutics, Inc. Common Stock's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.